Regulatory Considerations for Combination Products in the U.S.: A Comprehensive Guide

Published on 21/12/2025

Understanding FDA Regulatory Framework for Combination Products in the U.S.

Combination products—those that integrate drugs, devices, and/or biologics—have seen a surge in innovation and market relevance over the past decade. From insulin pens to drug-eluting stents and prefilled syringes, these products offer therapeutic synergies but also introduce significant regulatory challenges. In the United States, the U.S. Food and Drug Administration (FDA) has issued specific guidelines for managing such products under its Office of Combination Products (OCP). This article presents a tutorial-style breakdown of how combination products are regulated, classified, and approved in the U.S., emphasizing key compliance and GMP considerations.

Table of Contents

What Are Combination Products?

The FDA defines a combination product as a therapeutic and diagnostic product that combines any two or more of the following:

A drug and a device
A biologic and a device
A drug and a biologic
All three: drug, device, and biologic

Examples include:

Prefilled insulin cartridges (drug + device)
Drug-eluting coronary stents (drug + device)
Transdermal patches (drug + device)
Autoinjectors for biologics (biologic + device)

The FDA regulates combination products to ensure that safety, efficacy, and quality are maintained regardless of product complexity.

Legal Framework and FDA Authority:

Combination product regulation is guided by:

CFR Part 3: FDA product classification and jurisdiction

21 CFR Part 4: cGMP requirements for combination products

FDCA (Federal Food, Drug, and Cosmetic Act)

Public Health Service (PHS) Act

Classification by Primary Mode of Action (PMOA):

The FDA determines the lead regulatory center based on a product’s primary mode of action (PMOA). It may fall under:

CDER: Center for Drug Evaluation and Research
CBER: Center for Biologics Evaluation and Research
CDRH: Center for Devices and Radiological Health

The lead center manages the review while coordinating with other centers as needed. For example, a drug-device combination with a drug PMOA will be reviewed by CDER in consultation with CDRH.

How to Determine Product Classification:

Submit a Request for Designation (RFD) to the Office of Combination Products
FDA must respond within 60 calendar days
The designation determines the product’s PMOA and regulatory pathway

This is a critical step to avoid regulatory ambiguity.

Regulatory Pathways for Approval:

1. For Drug-led Combinations (PMOA = Drug):

Submit a New Drug Application (NDA) or Abbreviated NDA (ANDA). The device component must meet device regulations, labeling, and performance standards.

2. For Device-led Combinations (PMOA = Device):

File a Premarket Approval (PMA) or 510(k). The drug or biologic component’s safety and efficacy must be demonstrated via data.

3. For Biologic-led Combinations (PMOA = Biologic):

Submit a Biologics License Application (BLA). Review includes both CBER and potentially CDRH inputs.

The Investigational New Drug (IND) or Investigational Device Exemption (IDE) may also apply during early development stages.

cGMP Requirements for Combination Products:

Manufacturers must ensure adherence to cGMP requirements under 21 CFR Part 4. These include:

Drug GMPs under 21 CFR 210/211
Device QSRs under 21 CFR 820
Quality systems that integrate both sets of requirements

Manufacturing units often rely on robust Pharma SOPs to comply with dual regulatory expectations.

Labeling and Postmarket Requirements:

Combination products must adhere to labeling rules of the designated lead center:

Drugs: 21 CFR Part 201
Devices: 21 CFR Part 801
Biologics: 21 CFR Part 610

Postmarket safety monitoring must meet pharmacovigilance, device reporting, and biologics safety standards. This includes submission of:

FAERS (FDA Adverse Event Reporting System) reports
MAUDE (Manufacturer and User Facility Device Experience) data
Periodic Safety Update Reports (PSURs)

Unique Considerations for Combination Products:

Key regulatory nuances include:

Shared lot numbers and expiry dating for combination units
Integrated stability testing plans covering both components
Unified or hybrid packaging, storage, and transport protocols
Alignment with Stability Studies relevant to both drug and device aspects

Best Practices for Developers:

Engage with FDA early through pre-submission meetings
Submit a clear RFD before design finalization
Document PMOA and justification with clinical or functional data
Establish cross-functional QA systems incorporating both device and drug regulations
Utilize real-world evidence and patient-use data where possible

Emerging Trends and Regulatory Evolution:

As technology evolves, the FDA is increasingly adopting a lifecycle approach to regulate combination products. Recent guidance encourages:

Use of digital tools in delivery devices
Leveraging GMP validation for cross-compliance audits
Greater transparency and collaboration between FDA centers

Conclusion:

The regulation of combination products in the U.S. involves a layered and center-coordinated process based on the product’s primary mode of action. Proper classification, regulatory pathway selection, compliance with 21 CFR Part 4, and robust QA systems are pivotal for successful approval. With the right strategy and early FDA engagement, combination product developers can navigate the complex U.S. regulatory landscape efficiently while ensuring product safety and efficacy.